Literature DB >> 9305596

Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho).

H Kiyoi1, T Naoe, S Yokota, M Nakao, S Minami, K Kuriyama, A Takeshita, K Saito, S Hasegawa, S Shimodaira, J Tamura, C Shimazaki, K Matsue, H Kobayashi, N Arima, R Suzuki, H Morishita, H Saito, R Ueda, R Ohno.   

Abstract

FLT3 is a member of receptor tyrosine kinases expressed in leukemia cells, as well as in hematopoietic stem cells. Recently, a somatic alteration of the FLT3 gene was found in acute myeloid leukemia, as an internal tandem duplication (FLT3/ITD) which caused elongation of the juxtamembrane (JM) domain of FLT3. Here we characterized the FLT3/ITD and investigated its clinical significance in acute promyelocytic leukemia (APL). Seventy-four newly diagnosed patients with APL, who were treated with the same protocol in a multi-institutional study, were studied for the FLT3/ITD. Genomic and message sequences of the FLT3 gene were amplified by means of polymerase chain reaction (PCR), and elongated PCR products were sequenced. Fifteen patients (20.3%) had FLT3/ITD, all of which were transcribed in frame. Location of the duplicated fragments (six to 30 amino acids) varied from patient to patient. However, they always contained either Y591 or Y599, but the tyrosine kinase domain was not significantly affected. This finding implied that signal transduction of FLT3 is amplified by the duplication. Clinically, the presence of FLT3/ITD was related to high peripheral white blood cell counts as well as peripheral leukemia cell counts (P < 0.0001), high LDH level (P = 0.04), and low fibrinogen concentration (P = 0.04). These data suggest that FLT3/ITD plays a significant role in progression of APL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9305596     DOI: 10.1038/sj.leu.2400756

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  61 in total

1.  Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.

Authors:  Kathleen M Murphy; Mark Levis; Michael J Hafez; Tanya Geiger; Lisa C Cooper; B Douglas Smith; Donald Small; Karin D Berg
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

2.  Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.

Authors:  Harry Iland; Ken Bradstock; John Seymour; Mark Hertzberg; Andrew Grigg; Kerry Taylor; John Catalano; Paul Cannell; Noemi Horvath; Sandra Deveridge; Peter Browett; Tim Brighton; Li Chong; Francisca Springall; Juliet Ayling; Alberto Catalano; Shane Supple; Marnie Collins; Juliana Di Iulio; John Reynolds
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

3.  PML-RAR{alpha} and Dnmt3a1 cooperate in vivo to promote acute promyelocytic leukemia.

Authors:  Deepa Subramanyam; Cassandra D Belair; Keegan Q Barry-Holson; Haijiang Lin; Scott C Kogan; Emmanuelle Passegué; Robert Blelloch
Journal:  Cancer Res       Date:  2010-09-21       Impact factor: 12.701

4.  Establishment of a stroma-dependent human acute myelomonocytic leukemia cell line, NAMO-2, with FLT3 tandem duplication.

Authors:  Akihiro Abe; Hitoshi Kiyoi; Manabu Ninomiya; Tomio Yamazaki; Takuhei Murase; Kazutaka Ozeki; Momoko Suzuki; Fumihiko Hayakawa; Akira Katsumi; Nobuhiko Emi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

Review 5.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

Review 6.  Clinical significance of FLT3 in leukemia.

Authors:  Hitoshi Kiyoi; Masamitsu Yanada; Kazutaka Ozekia
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

7.  Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia.

Authors:  Brian V Balgobind; Marry M Van den Heuvel-Eibrink; Renee X De Menezes; Dirk Reinhardt; Iris H I M Hollink; Susan T J C M Arentsen-Peters; Elisabeth R van Wering; Gertjan J L Kaspers; Jacqueline Cloos; Evelien S J M de Bont; Jean-Michel Cayuela; Andre Baruchel; Claus Meyer; Rolf Marschalek; Jan Trka; Jan Stary; H Berna Beverloo; Rob Pieters; C Michel Zwaan; Monique L den Boer
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

8.  Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.

Authors:  Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; Wolfgang Kern; Tamara Alpermann; Torsten Haferlach
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

9.  Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype.

Authors:  Tadayuki Akagi; Seishi Ogawa; Martin Dugas; Norihiko Kawamata; Go Yamamoto; Yasuhito Nannya; Masashi Sanada; Carl W Miller; Amanda Yung; Susanne Schnittger; Torsten Haferlach; Claudia Haferlach; H Phillip Koeffler
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

10.  Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia.

Authors:  Letetia Jones; Guangwei Wei; Sabina Sevcikova; Vernon Phan; Sachi Jain; Angell Shieh; Jasmine C Y Wong; Min Li; Joshua Dubansky; Mei Lin Maunakea; Rachel Ochoa; George Zhu; Thelma R Tennant; Kevin M Shannon; Scott W Lowe; Michelle M Le Beau; Scott C Kogan
Journal:  J Exp Med       Date:  2010-11-08       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.